Economic evaluation of five first-line PD-(L)1 inhibitors for treating non-squamous non-small cell lung cancer in China: A cost-effectiveness analysis based on network meta-analysis

Background and objective: Non-small cell lung cancer (NSCLC) is one of the most malignant cancer types that causes substantial economic burden in China. This study aimed to evaluate the cost-effectiveness of five first-line anti-PD-(L)1 treatments, including sintilimab, camrelizumab, atezolizumab, p...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xi, Zhao, Mingye, Tian, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067912/
https://www.ncbi.nlm.nih.gov/pubmed/37021058
http://dx.doi.org/10.3389/fphar.2023.1119906

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067912/
https://www.ncbi.nlm.nih.gov/pubmed/37021058
http://dx.doi.org/10.3389/fphar.2023.1119906

Ejemplares similares